1. Home
  2. ZVRA vs VACH Comparison

ZVRA vs VACH Comparison

Compare ZVRA & VACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZVRA
  • VACH
  • Stock Information
  • Founded
  • ZVRA 2006
  • VACH 2023
  • Country
  • ZVRA United States
  • VACH United States
  • Employees
  • ZVRA N/A
  • VACH N/A
  • Industry
  • ZVRA Biotechnology: Pharmaceutical Preparations
  • VACH
  • Sector
  • ZVRA Health Care
  • VACH
  • Exchange
  • ZVRA Nasdaq
  • VACH NYSE
  • Market Cap
  • ZVRA 381.0M
  • VACH 321.3M
  • IPO Year
  • ZVRA 2015
  • VACH 2024
  • Fundamental
  • Price
  • ZVRA $7.15
  • VACH N/A
  • Analyst Decision
  • ZVRA Strong Buy
  • VACH
  • Analyst Count
  • ZVRA 8
  • VACH 0
  • Target Price
  • ZVRA $22.29
  • VACH N/A
  • AVG Volume (30 Days)
  • ZVRA 542.5K
  • VACH 7.9K
  • Earning Date
  • ZVRA 05-07-2025
  • VACH 01-01-0001
  • Dividend Yield
  • ZVRA N/A
  • VACH N/A
  • EPS Growth
  • ZVRA N/A
  • VACH N/A
  • EPS
  • ZVRA N/A
  • VACH 0.26
  • Revenue
  • ZVRA $23,612,000.00
  • VACH N/A
  • Revenue This Year
  • ZVRA $267.44
  • VACH N/A
  • Revenue Next Year
  • ZVRA $90.10
  • VACH N/A
  • P/E Ratio
  • ZVRA N/A
  • VACH $39.79
  • Revenue Growth
  • ZVRA N/A
  • VACH N/A
  • 52 Week Low
  • ZVRA $4.20
  • VACH $9.95
  • 52 Week High
  • ZVRA $9.76
  • VACH $11.20
  • Technical
  • Relative Strength Index (RSI)
  • ZVRA 45.68
  • VACH N/A
  • Support Level
  • ZVRA $6.77
  • VACH N/A
  • Resistance Level
  • ZVRA $7.22
  • VACH N/A
  • Average True Range (ATR)
  • ZVRA 0.45
  • VACH 0.00
  • MACD
  • ZVRA -0.00
  • VACH 0.00
  • Stochastic Oscillator
  • ZVRA 61.74
  • VACH 0.00

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

About VACH VOYAGER ACQUISITION CORP.

Voyager Acquisition Corp is a blank check company.

Share on Social Networks: